Richard Shames - Protagonist Therapeutics Chief Medical Officer

PTGX Stock  USD 43.80  0.57  1.28%   

Executive

Dr. Richard S. Shames, M.D., serves as Chief Medical Officer of the Company. He currently also serves as Adjunct Associate Clinical Professor of Pediatrics at Stanford University. Prior to joining Protagonist, he served as Senior Vice President and Chief Medical Officer at Aldea Pharmaceuticals, from 2013 to 2015. Prior to Aldea, Dr. Shames was Distinguished Scientist, Clinical Research and Early Biologics Lead at Merck Co., Inc., from 2009 to 2013. Prior to joining Merck, Dr. Shames held positions of increasing responsibility at Facet Biotech, from 1999 to 2009, most recently as Therapeutic Head of Immunology and Senior Medical Director. Prior to Facet, Dr. Shames held full time clinical faculty positions in Pediatric Allergy and Clinical Immunology at Stanford University, from 1996 to 1999, and the University of California, San Francisco Schools of Medicine, from 1993 to 1996 since 2015.
Age 64
Tenure 9 years
Address 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160
Phone510 474 0170
Webhttps://www.protagonist-inc.com
Shames received his M.D. from University of California, Davis School of Medicine and received a B.S. in Biological Sciences from Stanford University.

Protagonist Therapeutics Management Efficiency

The company has return on total asset (ROA) of 0.2035 % which means that it generated a profit of $0.2035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4069 %, meaning that it created $0.4069 on every $100 dollars invested by stockholders. Protagonist Therapeutics' management efficiency ratios could be used to measure how well Protagonist Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.29 in 2024. Other Current Assets is likely to rise to about 14.7 M in 2024, whereas Total Assets are likely to drop slightly above 204.1 M in 2024.
Protagonist Therapeutics currently holds 1.14 M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Protagonist Therapeutics has a current ratio of 7.44, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Protagonist Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Deborah MBARelay Therapeutics
N/A
Daniel SimonIdeaya Biosciences
N/A
Kevin McManusSyndax Pharmaceuticals
55
Eric MosbrookerAvidity Biosciences
57
Pharm MPHX4 Pharmaceuticals
N/A
Elly MDDay One Biopharmaceuticals
N/A
Christopher MartinVerona Pharma PLC
N/A
Shannon CampbellMerus BV
N/A
Francis BurrowsKura Oncology
N/A
Robyn MAAcumen Pharmaceuticals
N/A
John NorthcottArvinas
46
Ostra JewellVerona Pharma PLC
N/A
Tara MPHVerona Pharma PLC
48
Jonathan JDStoke Therapeutics
34
Pamela EspositoReplimune Group
50
B ASIAVerona Pharma PLC
57
Mark WinderlichHookipa Pharma
38
Erika JonesBlack Diamond Therapeutics
39
Thomas LeggettStoke Therapeutics
47
Jan SmithRevolution Medicines
N/A
Kathleen FordKura Oncology
77
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Protagonist Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 127 people. Protagonist Therapeutics (PTGX) is traded on NASDAQ Exchange in USA. It is located in 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160 and employs 125 people. Protagonist Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Protagonist Therapeutics Leadership Team

Elected by the shareholders, the Protagonist Therapeutics' board of directors comprises two types of representatives: Protagonist Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protagonist. The board's role is to monitor Protagonist Therapeutics' management team and ensure that shareholders' interests are well served. Protagonist Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protagonist Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Mohammad Masjedizadeh, Executive Officer
Abha Bommireddi, Executive Management
Ashok Bhandari, Vice President - Chemistry
Matthew Gosling, Executive Counsel
Richard Shames, Chief Medical Officer
Dinesh Patel, President CEO, Director
David Liu, Chief Scientific Officer, Head of Research & Development
Carena Spivey, Senior Resources
Suneel Gupta, Executive Vice President of Clinical Operations and Clinical Pharmacology
Mark Smythe, Vice President -Technology & Alliances
Scott MD, Executive Gastroenterology
FACP MD, Chief Officer
Carter King, Executive Development
Asif Ali, Executive Officer

Protagonist Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protagonist Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Protagonist Stock Analysis

When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.